Payment overview · 2025
General Payments
$1,426.03
61 reported records · 12 companies
Healthcare provider profile · identity verified
Jeffrey Steven Hampton, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HALLS, TN · NPI 1275702672
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Steven Hampton, FNP received $1,426.03 in general payments during 2025 across 61 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $340.50 | 23.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $291.25 | 20.4% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $228.74 | 16.0% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.08 | 12.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $91.83 | 6.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $90.45 | 6.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.45 | 4.0% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $54.61 | 3.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.25 | 3.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.38 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.62 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $9.87 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,426.03 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $340.50 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $257.03 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $205.55 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $182.28 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.74 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $115.09 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.45 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $54.61 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.25 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.25 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.19 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $9.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $7.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 87 |
| Famotidine | Famotidine | 361 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 350 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 79 |
| Prednisone | Prednisone | 308 | 182 |
| Gabapentin | Gabapentin | 304 | 54 |
| Losartan Potassium | Losartan Potassium | 289 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 65 |
| Alprazolam | Alprazolam | 247 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 237 | 52 |
| Furosemide | Furosemide | 229 | 57 |
| Lisinopril | Lisinopril | 221 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 48 |
| Simvastatin | Simvastatin | 197 | 39 |
| Azithromycin | Azithromycin | 186 | 146 |
| Potassium Chloride | Potassium Chloride | 185 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 46 |
| Metformin Hcl | Metformin Hcl | 181 | 46 |
| Montelukast Sodium | Montelukast Sodium | 181 | 38 |
| Omeprazole | Omeprazole | 161 | 41 |
| Buspirone Hcl | Buspirone Hcl | 157 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 29 |
| Trazodone Hcl | Trazodone Hcl | 155 | 33 |
| Eliquis | Apixaban | 147 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 26 |
| Tramadol Hcl | Tramadol Hcl | 139 | 23 |
| Clonazepam | Clonazepam | 136 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 36 |
| Celecoxib | Celecoxib | 120 | 36 |
| Meloxicam | Meloxicam | 119 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 42 |
| Jardiance | Empagliflozin | 116 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 110 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 50 |
| Carvedilol | Carvedilol | 95 | 23 |
| Sertraline Hcl | Sertraline Hcl | 95 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 91 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 18 |
| Valsartan | Valsartan | 81 | 15 |
| Pregabalin | Pregabalin | 80 | 15 |
| Levofloxacin | Levofloxacin | 78 | 54 |
| Glimepiride | Glimepiride | 75 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 12 |
| Lorazepam | Lorazepam | 74 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 14 |
| Ezetimibe | Ezetimibe | 69 | 23 |
| Januvia | Sitagliptin Phosphate | 69 | 15 |
| Methocarbamol | Methocarbamol | 69 | 26 |
| Fluconazole | Fluconazole | 68 | 41 |
| Cephalexin | Cephalexin | 65 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 11 |
| Levetiracetam | Levetiracetam | 62 | suppressed |
| Spironolactone | Spironolactone | 61 | 14 |
| Donepezil Hcl | Donepezil Hcl | 60 | 20 |
| Baclofen | Baclofen | 59 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 16 |
| Ozempic | Semaglutide | 55 | 17 |
| Allopurinol | Allopurinol | 54 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 11 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 13 |
| Promethazine Hcl | Promethazine Hcl | 47 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Mupirocin | Mupirocin | 43 | 34 |
| Repatha Sureclick | Evolocumab | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 34 |
| Ibuprofen | Ibuprofen | 42 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 14 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 14 |
| Diazepam | Diazepam | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 12 |
| Movantik | Naloxegol Oxalate | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | 15 |
| Ondansetron Odt | Ondansetron | 34 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Rexulti | Brexpiprazole | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 18 |
| Glipizide | Glipizide | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Naproxen | Naproxen | 30 | 15 |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 29 | suppressed |
| Nystatin | Nystatin | 29 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 14 |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Metronidazole | Metronidazole | 22 | 20 |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,426.03 · 61 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error